Appili Therapeutics Announces Proposed Non-Brokered Private Placement

Article content

About Appili Therapeutics

Article content

Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

Article content

Forward-Looking Information

Article content

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Article content

Article content

Forward-looking statements in this news release include, but are not limited to: statements with respect to the use of proceeds, intended closing of the Private Placement and when shareholder approval of the Warrants and Broker Warrants will be sought. Actual results and developments may differ materially from those contemplated by these statements. Such forward-looking statements are based on certain assumptions of the Company’s management, including timing of certain events related to the Private Placement. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect.

Article content

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks relating to: (i) ability to close the Private Placement and the timing thereof; and (ii) the risk factors listed in the annual information form of the Company dated June 25, 2025 and other important factors in the Appili’s other filings with the Canadian securities regulators on SEDAR+. Consequently, the reader is cautioned not to place undue reliance on the forward-looking statements and information contained in this press release.

Article content

Article content

The statements in this press release are made as of the date of this release. Appili disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Article content

No securities regulatory authority has either approved or disapproved of the contents of this press release. 

Article content

Article content

Article content

Article content

Article content

Article content

Article content

Article content